LaCasce on Bispecific Antibodies Transforming Lymphoma Care

These therapies are showing significant impact in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, particularly in relapsed and refractory cases. Early studies in frontline settings are reporting high complete remission rates with promising durability.

LaCasce notes that bispecific antibodies are now being incorporated into investigator-initiated trials, both alone and with novel oral agents. In DLBCL, these therapies have demonstrated strong efficacy, especially in patients relapsing after chimeric antigen receptor (CAR) T-cell therapy. As randomized studies progress, researchers aim to confirm their role in achieving longer, durable remissions.

However, she cautions about the increased risk of infections associated with these treatments. She emphasizes the need for proactive management of toxicity to ensure patient safety as these therapies continue to advance in clinical practice.

Transcription:

0:10 | These are really making an impact in both diffuse large B-cell lymphoma and follicular lymphoma. We have seen pretty amazing responses in the relapsed and refractory setting, and we are seeing these investigator-initiated studies in the frontline setting with very high complete remission rates, and the durability is looking very promising. I think we are going to continue to see these studies, maybe with or without other novel agents, like oral agents, and it is really moving forward. The same is true in diffuse large B-cell lymphoma. Again, we saw pretty remarkable activity initially in patients who had relapsed after CAR T-cell therapy. Now there have been a number of studies incorporating them upfront, and the overall and complete response rates look good. We are having these randomized studies to try to prove that these result in longer, durable remissions.

1:14 | One thing we will have to keep an eye on is the toxicity profile. There is definitely an increased risk of infection. I think the more that we can pay attention to that and try to figure out how to mitigate that and be proactive is going to be important.